Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, et al.
Modern Rheumatology (2019) Vol. 30, Iss. 1, pp. 36-43
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani, Katharina Meier, Kamran Ghoreschi
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 247
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley Cohen, Ronald van Vollenhoven, Kevin Winthrop, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 304-311
Open Access | Times Cited: 189
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
Jacopo Angelini, Rossella Talotta, Rossana Roncato, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 150
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 101-115
Closed Access | Times Cited: 51
JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini, Iain B. McInnes, Stefan Siebert
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 102
Cardiovascular effects of approved drugs for rheumatoid arthritis
Fabiola Atzeni, Javier Rodríguez‐Carrio, Călin D. Popa, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 5, pp. 270-290
Closed Access | Times Cited: 79
Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential
Hong‐Tai Tzeng, I‐Tsu Chyuan, Jenn‐Haung Lai
Biochemical Pharmacology (2021) Vol. 193, pp. 114760-114760
Closed Access | Times Cited: 69
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 47
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Kevin Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 206-213
Open Access | Times Cited: 53
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Kosuke Ebina, Tôru Hirano, Yuichi Maeda, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials
Wenting Cai, Rui Tong, Yue Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, et al.
Lara D. Veeken (2020) Vol. 59, Iss. 11, pp. 3303-3313
Open Access | Times Cited: 49
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 41
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
Shunsuke Mori, Fumihiko Ogata, Ryusuke Tsunoda
Clinical Rheumatology (2021) Vol. 40, Iss. 11, pp. 4457-4471
Open Access | Times Cited: 34
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003885-e003885
Open Access | Times Cited: 5
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
Magdalena Massalska, Włodzimierz Maśliński, Marzena Ciechomska
Cells (2020) Vol. 9, Iss. 8, pp. 1876-1876
Open Access | Times Cited: 35
Treatment strategies for elderly-onset rheumatoid arthritis in the new era
Takahiko Sugihara
Modern Rheumatology (2021) Vol. 32, Iss. 3, pp. 493-499
Closed Access | Times Cited: 28
JAK inhibitors in 2019, synthetic review in 10 points
R. Müller
European Journal of Internal Medicine (2019) Vol. 66, pp. 9-17
Closed Access | Times Cited: 34
Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series
Yan‐hong Sun, Xiao‐Yong Man, Xiuyun Xuan, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 11
Open Access | Times Cited: 19
Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review
Kevin Winthrop, Yoshiya Tanaka, Eun Bong Lee, et al.
Clinical and Experimental Rheumatology (2022) Vol. 40, Iss. 1, pp. 162-172
Open Access | Times Cited: 18
Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
Michiaki Takagi, Tatsuya Atsumi, Hiroaki Matsuno, et al.
Modern Rheumatology (2022) Vol. 33, Iss. 4, pp. 647-656
Closed Access | Times Cited: 18
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, et al.
Arthritis Research & Therapy (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry
Nobunori Takahashi, Shuji Asai, Tomonori Kobayakawa, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 25
Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
Young‐Eun Kim, Ye‐Jee Kim, Dae Hyun Jeong, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 65, pp. 152362-152362
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top